Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81703 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL12449339 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL13430521 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL7636456 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL12449351 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL23196361 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL12522387 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL15291348 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL320044 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT | |
| SCHEMBL15697973 | 1.00 | EPHX1 (0.57) | EPHX1ALDH1A1HPGDCYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773445-B1 | RETINOL REPLACEMENT IN SKIN TREATMENT | SYMRISE AG (DE) | 2024-07-24 | — | — | EP | claimed |
| US-20240058243-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | SYMRISE AG (DE) | 2024-02-22 | — | — | US | claimed |
| EP-4259287-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | Symrise AG (DE) | 2023-10-18 | — | — | EP | claimed |
| EP-3081207-B1 | USE OF A LIPOSOME COMPOSITION | SYMRISE AG (DE) | 2022-09-21 | — | — | EP | claimed |
| WO-2022122144-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | SYMRISE AG (DE) | 2022-06-16 | — | — | WO | claimed |
| EP-4103144-B1 | COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4192614-B1 | PROCESS FOR THE PREPARATION OF MICROCAPSULES | SYMRISE AG (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4110277-B1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725476-A2 | COMPOSITIONS FOR REDUCING SALTY TASTE AND USES THEREOF | Firmenich SA (CH) | 2026-04-15 | — | — | EP | disclosed |
| EP-3911172-B1 | COMBINATION OF SATIETY COMPONENTS WITH ARGININE | SYMRISE AG (DE) | 2026-04-15 | — | — | EP | disclosed |
| EP-3045161-B1 | Use of active mixtures of 1,2-hexanediol and 1,2-octanediol in cosmetic, pharmaceutical or dermatological emulsions | SYMRISE AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4025675-B1 | A PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-20220047476-A1 | A METHOD FOR FIGHTING FEMALE BODY ODORS | SYMRISE AG (DE) | 2022-02-17 | — | — | US | disclosed |
| EP-1750525-B1 | PHYSIOLOGICAL COOLING COMPOSITIONS | RENESSENZ LLC (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7968744-B2 | Physiological coolants based on lactoyl esters of menthyl lactate | RENESSENZ, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100311833-A1 | Physiological coolants based on lactoyl esters of menthyl lactate | RENESSENZ LLC | 2010-12-09 | — | — | US | disclosed |
| US-7652067-B2 | Aqueous compositions containing monoester salts | MILLENIUM SPECIALTY CHEMICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7482378-B2 | Physiological cooling compositions | MILLENIUM SPECIALTY CHEMICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080085933-A1 | Aqueous compositions containing monoester salts | PINOVA HOLDINGS, INC | 2008-04-10 | — | — | US | disclosed |
| WO-2008030312-A1 | AQUEOUS COMPOSITIONS CONTAINING MONOESTER SALTS | MILLENNIUM SPECIALTY CHEMICALS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311833-A1 | Physiological coolants based on lactoyl esters of menthyl lactate | LDHA, MDH1, MDH2 | EPHX1 1811/4885ALDH1A1 260/4885HPGD 347/4885 |
| US-20240058243-A1 | A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES | MGLL, GCDH, GK | EPHX1 1246/4885ALDH1A1 935/4885HPGD 974/4885 |
| US-20220047476-A1 | A METHOD FOR FIGHTING FEMALE BODY ODORS | SHBG, C5, CUTA | EPHX1 2118/4885ALDH1A1 704/4885HPGD 3389/4885 |
| US-20080085933-A1 | Aqueous compositions containing monoester salts | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADH1C, PUF60 | EPHX1 2113/4885ALDH1A1 416/4885HPGD 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.